BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 10357952)

  • 81. Analysis of the bleeding pattern in assisted reproduction cycles with luteal phase supplementation using vaginal micronized progesterone.
    Romàn E; Aytoz A; Smitz JE; Faguer B; Camus M; Van Steirteghem AC; Devroey P
    Hum Reprod; 2000 Jul; 15(7):1435-9. PubMed ID: 10875847
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Trial of support treatment with human chorionic gonadotrophin in the luteal phase after treatment with buserelin and human menopausal gonadotrophin in women taking part in an in vitro fertilisation programme.
    Smith EM; Anthony FW; Gadd SC; Masson GM
    BMJ; 1989 Jun; 298(6686):1483-6. PubMed ID: 2503080
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Effect of HCG-day serum progesterone and oestradiol concentrations on pregnancy outcomes in GnRH agonist cycles.
    Wu Z; Li R; Ma Y; Deng B; Zhang X; Meng Y; Chen X; Liu P; Qiao J
    Reprod Biomed Online; 2012 May; 24(5):511-20. PubMed ID: 22417667
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles.
    Tesarik J; Hazout A; Mendoza-Tesarik R; Mendoza N; Mendoza C
    Hum Reprod; 2006 Oct; 21(10):2572-9. PubMed ID: 16926261
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients.
    Goldrat O; Gervy C; Englert Y; Delbaere A; Demeestere I
    Hum Reprod; 2015 Sep; 30(9):2184-9. PubMed ID: 26109617
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of r-FSH alone and in combination with r-LH.
    Levi-Setti PE; Cavagna M; Bulletti C
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):212-6. PubMed ID: 16377062
    [TBL] [Abstract][Full Text] [Related]  

  • 87. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles.
    Yu S; Long H; Chang HY; Liu Y; Gao H; Zhu J; Quan X; Lyu Q; Kuang Y; Ai A
    Hum Reprod; 2018 Feb; 33(2):229-237. PubMed ID: 29300975
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Initiation of ovarian stimulation independent of the menstrual cycle: a case-control study.
    Buendgen NK; Schultze-Mosgau A; Cordes T; Diedrich K; Griesinger G
    Arch Gynecol Obstet; 2013 Oct; 288(4):901-4. PubMed ID: 23545834
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Luteal phase support with estradiol and progesterone versus progesterone alone in GnRH antagonist ICSI cycles: a randomized controlled study.
    Ismail Madkour WA; Noah B; Abdel Hamid AM; Zaheer H; Al-Bahr A; Shaeer M; Moawad A
    Hum Fertil (Camb); 2016 Jun; 19(2):142-9. PubMed ID: 27434094
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg.
    Olivennes F; Alvarez S; Bouchard P; Fanchin R; Salat-Baroux J; Frydman R
    Hum Reprod; 1998 Sep; 13(9):2411-4. PubMed ID: 9806259
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Impact of clomiphene citrate during ovarian stimulation on the luteal phase after GnRH agonist trigger.
    Derksen L; Tournaye H; Stoop D; Van Vaerenbergh I; Bourgain C; Polyzos NP; Haentjens P; Blockeel C
    Reprod Biomed Online; 2014 Mar; 28(3):359-68. PubMed ID: 24456700
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Comparison of modified agonist, mild-stimulation and antagonist protocols for in vitro fertilization in patients with diminished ovarian reserve.
    Yu R; Jin H; Huang X; Lin J; Wang P
    J Int Med Res; 2018 Jun; 46(6):2327-2337. PubMed ID: 29695208
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Comparison of cryopreservation outcome with human pronuclear stage oocytes obtained by the GnRH antagonist, cetrorelix, and GnRH agonists.
    Nikolettos N; Al-Hasani S; Felberbaum R; Demirel LC; Riethmüller-Winzen H; Reissmann T; Schöpper B; Sturm R; Diedrich K
    Eur J Obstet Gynecol Reprod Biol; 2000 Nov; 93(1):91-5. PubMed ID: 11000511
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles.
    Tavaniotou A; Devroey P
    Reprod Biomed Online; 2006 Sep; 13(3):326-30. PubMed ID: 16984758
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Precycle administration of GnRH antagonist and microdose HCG decreases clinical pregnancy rates without affecting embryo quality and blastulation.
    Bukulmez O; Rehman KS; Langley M; Carr BR; Nackley AC; Doody KM; Doody KJ
    Reprod Biomed Online; 2006 Oct; 13(4):465-75. PubMed ID: 17007662
    [TBL] [Abstract][Full Text] [Related]  

  • 96. No influence of body weight on pregnancy rate in patients treated with cetrorelix according to the single- and multiple-dose protocols.
    Engel JB; Ludwig M; Junge K; Howles CM; Diedrich K
    Reprod Biomed Online; 2003 Jun; 6(4):482-7. PubMed ID: 12831598
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Perinatal outcome of pregnancy after GnRH antagonist (ganirelix) treatment during ovarian stimulation for conventional IVF or ICSI: a preliminary report.
    Olivennes F; Mannaerts B; Struijs M; Bonduelle M; Devroey P
    Hum Reprod; 2001 Aug; 16(8):1588-91. PubMed ID: 11473947
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Continuous administration of gonadotrophin-releasing hormone agonist during the luteal phase in IVF.
    Fujii S; Sato S; Fukui A; Kimura H; Kasai G; Saito Y
    Hum Reprod; 2001 Aug; 16(8):1671-5. PubMed ID: 11473961
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Luteal support with micronized progesterone following in-vitro fertilization using a down-regulation protocol with gonadotrophin-releasing hormone agonist: a comparative study between vaginal and oral administration.
    Friedler S; Raziel A; Schachter M; Strassburger D; Bukovsky I; Ron-El R
    Hum Reprod; 1999 Aug; 14(8):1944-8. PubMed ID: 10438404
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Effect of antagonists vs agonists on in vitro fertilization outcome.
    Check ML; Check JH; Choel JK; Davies E; Kiefer D
    Clin Exp Obstet Gynecol; 2004; 31(4):257-9. PubMed ID: 15672958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.